Celularity appoints Richard J. Berman to Board; reduces board from 7 to 6

Celularity Inc

Richard J. Berman appointed as Class II director, effective Aug 27, 2024, to fill vacancy left by Robin L. Smith.
Berman received an option to purchase 118,111 shares at $3.01/share, vesting in three equal annual installments.
Board reduced from seven to six directors following Marc Mazur's departure; Class III reduced from two to one.
Berman brings over 40 years of VC and M&A experience; served on boards of six companies over $1B market value.
He was appointed to the Audit Committee; qualifies as independent under Nasdaq rules.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard J. Berman

Director

CELU · Celularity Inc

Effective: 2024-08-27
Filed: August 28, 2024, 7:59 PM ET

On August 27, 2024, the board of directors, or the Board, of Celularity Inc., or Celularity, appointed Richard J. Berman, as a Class II director to fill the vacancy left by the resignation of Robin L. Smith, M.D.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard J. Berman was appointed as Director at Celularity Inc.

Action: appointed
Role: Director

Exact text from the filing

On August 27, 2024, the board of directors, or the Board, of Celularity Inc., or Celularity, appointed Richard J. Berman, as a Class II director to fill the vacancy left by the resignation of Robin L. Smith, M.D.

View on SEC.gov

Celularity Inc filing history →

Source: SEC EDGAR

accession 0001493152-24-034216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.